These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 21746958)

  • 1. Emergence of ertapenem resistance in an Escherichia coli clinical isolate producing extended-spectrum beta-lactamase AmpC.
    Guillon H; Tande D; Mammeri H
    Antimicrob Agents Chemother; 2011 Sep; 55(9):4443-6. PubMed ID: 21746958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of resistance to beta-lactams and characterization of beta-lactamases in Escherichia coli isolates from children in Tunisia.
    Réjiba S; Kechrid A
    J Chemother; 2007 Aug; 19(4):382-7. PubMed ID: 17855181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of extended spectrum beta lactamase and AmpC beta lactamase producers among Escherichia coli isolates in a tertiary care hospital in Jaipur.
    Sinha P; Sharma R; Rishi S; Sharma R; Sood S; Pathak D
    Indian J Pathol Microbiol; 2008; 51(3):367-9. PubMed ID: 18723959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of the susceptibilities of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. strains to ertapenem and other carbapenems].
    Kuzucu C; Yetkin F; Görgeç S; Ersoy Y
    Mikrobiyol Bul; 2011 Jan; 45(1):28-35. PubMed ID: 21341156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenem MICs in Escherichia coli and Klebsiella Species Producing Extended-Spectrum β-Lactamases in Critical Care Patients from 2001 to 2009.
    Johnson JK; Robinson GL; Pineles LL; Ajao AO; Zhao L; Albrecht JS; Harris AD; Thom KA; Furuno JP
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28167543
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative in vitro activity of ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolated in Spain.
    Hernández JR; Velasco C; Romero L; Martínez-Martínez L; Pascual A
    Int J Antimicrob Agents; 2006 Nov; 28(5):457-9. PubMed ID: 17008066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vitro emergence of ertapenem resistance in Escherichia coli producing extended-spectrum β-lactamase].
    Villar HE; Jugo MB; Visser M; Hidalgo M; Hidalgo G; Maccallini GC
    Rev Esp Quimioter; 2014 Mar; 27(1):51-5. PubMed ID: 24676243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of extended-spectrum AmpC (ESAC) beta-lactamases to carbapenem resistance in Escherichia coli.
    Mammeri H; Nordmann P; Berkani A; Eb F
    FEMS Microbiol Lett; 2008 May; 282(2):238-40. PubMed ID: 18371063
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular epidemiology of extended-spectrum β-lactamase-, AmpC β-lactamase- and carbapenemase-producing Escherichia coli and Klebsiella pneumoniae isolated from Canadian hospitals over a 5 year period: CANWARD 2007-11.
    Denisuik AJ; Lagacé-Wiens PR; Pitout JD; Mulvey MR; Simner PJ; Tailor F; Karlowsky JA; Hoban DJ; Adam HJ; Zhanel GG;
    J Antimicrob Chemother; 2013 May; 68 Suppl 1():i57-65. PubMed ID: 23587779
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural Alteration of OmpR as a Source of Ertapenem Resistance in a CTX-M-15-Producing Escherichia coli O25b:H4 Sequence Type 131 Clinical Isolate.
    Dupont H; Choinier P; Roche D; Adiba S; Sookdeb M; Branger C; Denamur E; Mammeri H
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Frequent emergence of porin-deficient subpopulations with reduced carbapenem susceptibility in ESBL-producing Escherichia coli during exposure to ertapenem in an in vitro pharmacokinetic model.
    Tängdén T; Adler M; Cars O; Sandegren L; Löwdin E
    J Antimicrob Chemother; 2013 Jun; 68(6):1319-26. PubMed ID: 23478794
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacodynamic activity of ertapenem versus genotypically characterized extended-spectrum β-lactamase (ESBL)-, KPC- or NDM-producing Escherichia coli with reduced susceptibility or resistance to ertapenem using an in vitro model.
    Zhanel GG; Denisuik A; Vashisht S; Yachison C; Adam HJ; Hoban DJ
    J Antimicrob Chemother; 2014 Sep; 69(9):2448-52. PubMed ID: 24827891
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
    Pires J; Taracila M; Bethel CR; Doi Y; Kasraian S; Tinguely R; Sendi P; Bonomo RA; Endimiani A
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7483-8. PubMed ID: 26392491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Susceptibility of European Escherichia coli clinical isolates from intra-abdominal infections, extended-spectrum β-lactamase occurrence, resistance distribution, and molecular characterization of ertapenem-resistant isolates (SMART 2008-2009).
    Hawser SP; Bouchillon SK; Lascols C; Hackel M; Hoban DJ; Badal RE; Cantón R
    Clin Microbiol Infect; 2012 Mar; 18(3):253-9. PubMed ID: 21635662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and characteristics of ertapenem-nonsusceptible Escherichia coli in a Taiwanese university hospital, 1999 to 2007.
    Yan JJ; Wu JJ; Lee CC; Ko WC; Yang FC
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1417-25. PubMed ID: 20700614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of ertapenem and other carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella pneumoniae clinical isolates in a tertiary care center in Turkey.
    Kiremitci A; Dinleyici EC; Erben N; Durmaz G; Yargic ZA; Aybey AD; Usluer G
    Expert Opin Pharmacother; 2008 Jun; 9(9):1441-9. PubMed ID: 18518776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence and molecular characterization of clinical isolates of Escherichia coli expressing an AmpC phenotype.
    Jørgensen RL; Nielsen JB; Friis-Møller A; Fjeldsøe-Nielsen H; Schønning K
    J Antimicrob Chemother; 2010 Mar; 65(3):460-4. PubMed ID: 20097787
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Comparative activity of ertapenem against extended-spectrum beta-lactamase-producing or plasmid-mediated AmpC beta-lactamase-producing Klebsiella pneumoniae].
    Hernández JR; Conejo Mdel C; Pascual A
    Enferm Infecc Microbiol Clin; 2010 Jan; 28(1):27-30. PubMed ID: 19631421
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of carbapenem resistance among a collection of Enterobacteriaceae clinical isolates in a Texas city.
    Bennett JW; Mende K; Herrera ML; Yu X; Lewis JS; Wickes BL; Jorgensen JH; Murray CK
    Diagn Microbiol Infect Dis; 2010 Apr; 66(4):445-8. PubMed ID: 20226336
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Contributions of the AmpC beta-lactamase and the AcrAB multidrug efflux system in intrinsic resistance of Escherichia coli K-12 to beta-lactams.
    Mazzariol A; Cornaglia G; Nikaido H
    Antimicrob Agents Chemother; 2000 May; 44(5):1387-90. PubMed ID: 10770787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.